keyword
MENU ▼
Read by QxMD icon Read
search

Dapt score

keyword
https://www.readbyqxmd.com/read/29138929/safety-and-feasibility-study-of-holmium-laser-enucleation-of-the-prostate-holep-on-patients-receiving-dual-antiplatelet-therapy-dapt
#1
Jie Sun, An Shi, Zhen Tong, Wei Xue
OBJECTIVE: To evaluate the safety and feasibility of Holmium laser enucleation of the prostate (HoLEP) in patients receiving dual antiplatelet therapy (DAPT). METHODS: From March 2013 to August 2016, we retrospectively analyzed 1124 benign prostatic hyperplasia (BPH) patients undergoing HoLEP and divided into four groups: 56 cases receiving DAPT therapy (group A); 72 patients treated with continuous single antiplatelet (AP) therapy (group B); 41 patients treated with single AP therapy but intermittent during preoperative time (group C) and 955 cases had no AP therapy (group D)...
November 14, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/29131804/assessing-the-performance-of-the-precise-dapt-and-paris-risk-scores-for-predicting-1-year-out-of-hospital-bleeding-in-acute-coronary-syndrome-patients
#2
Emad Abu-Assi, Sergio Raposeiras-Roubin, Rafael Cobas-Paz, Berenice Caneiro-Queija, Cristina Martínez-Reglero, José Manuel Rodríguez-Rodríguez, Antonio Baz, Andrés Íñiguez-Romo
AIMS: PRECISE-DAPT and PARIS risk scores (RSs) were recently developed to bleeding risk assessment in percutaneous coronary intervention (PCI) patients treated with dual antiplatelet therapy (DAPT). We aimed to assess the performance of these RSs at predicting out-of-hospital bleeding in patients with acute coronary syndrome (ACS). METHODS AND RESULTS:  Retrospectively, we studied 1926 consecutive ACS patients treated with PCI and DAPT. The performance of RSs for predicting one-year BARC type 2, 3 or 5 bleeding and BARC type 3 or 5 bleeding was assessed and compared...
November 14, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29103068/antiplatelet-therapy-for-secondary-prevention-of-vascular-disease-complications
#3
REVIEW
Rahul R Goli, Mayur M Contractor, Ashwin Nathan, Sony Tuteja, Taisei Kobayashi, Jay Giri
PURPOSE OF REVIEW: Platelets are activated upon interaction with injured vascular endothelium to form a primary hemostatic plug. Pathogenic thrombosis driven by platelet aggregation can occur in the setting of vascular disease leading to ischemic events. The use of antiplatelet agents has become a mainstay for prevention of the secondary complications of vascular disease. This review summarizes seminal and recent literature related to this area. RECENT FINDINGS: Aspirin is a cornerstone of antiplatelet therapy for coronary artery disease and cerebrovascular disease for prevention of myocardial infarction, stroke, and vascular death...
November 4, 2017: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/29073947/lesion-complexity-and-outcomes-of-extended-dual-antiplatelet-therapy-after-percutaneous-coronary-intervention
#4
RANDOMIZED CONTROLLED TRIAL
Robert W Yeh, Dean J Kereiakes, P Gabriel Steg, Donald E Cutlip, Kevin J Croce, Joseph M Massaro, Laura Mauri
BACKGROUND: Subjects undergoing coronary stenting with complex lesion anatomy may experience different risks and benefits with prolonged dual antiplatelet therapy. OBJECTIVES: The authors assessed the effect of 30 months versus 12 months of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) based on the presence or absence of anatomically-complex target lesions. METHODS: In the DAPT Study, combined myocardial infarction (MI) or stent thrombosis and moderate/severe bleeding were assessed in enrolled (n = 25,416) and randomized (n = 11,554) subjects...
October 31, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29044393/duration-of-dual-antiplatelet-therapy-and-associated-outcomes-following-percutaneous-coronary-intervention-for-acute-myocardial-infarction-contemporary-practice-insights-from-the-canadian-observational-antiplatelet-study
#5
Juan J Russo, Shaun G Goodman, Akshay Bagai, Jean-Pierre Déry, Mary K Tan, Harold N Fisher, Xiang Zhang, Yajun Emily Zhu, Robert C Welsh, Anthony Della Siega, Andre Kokis, Brian Y L Wong, Mark Henderson, Sohrab Lutchmedial, Shahar Lavi, Shamir R Mehta, Andrew T Yan
Aims: There is a paucity of real-world, contemporary data of practice patterns and clinical outcomes following dual-antiplatelet therapy (DAPT) in acute myocardial infarction (AMI) patients treated with percutaneous coronary intervention (PCI). Methods and results: The Canadian Observational Antiplatelet Study was a prospective, multicentre, cohort study examining adenosine diphosphate receptor antagonist use following PCI for AMI. We compared practice patterns, patient characteristics, and clinical outcomes in relation to DAPT duration (<6 weeks, 6 weeks to <6 months, 6 to <12, and ≥12 months)...
October 1, 2017: European Heart Journal. Quality of Care & Clinical Outcomes
https://www.readbyqxmd.com/read/29035834/synergistic-effect-of-mild-hypothermia-and-the-notch-inhibitor-dapt-against-post-stroke-seizures
#6
Guo-Shuai Yang, Xiao-Yan Zhou, Xue-Fang An, Xuan-Jun Liu, Yan-Jun Zhang, Dan Yu
Seizure is a serious complication of stroke, indicating poor prognosis. Notch signaling is associated with neuronal activity. Inhibition of Notch signaling suppresses seizure activity induced by kainic acid. The present study investigated the effect of the Notch inhibitor, DAPT, alone or in combination with mild hypothermia, on post-stroke seizures. A global cerebral ischemia (GCI) model was performed in Sprague Dawley (SD) male rats. Seizure activity was evaluated by the frequency of seizure attacks, seizure severity scores, and seizure discharges...
October 13, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28982692/validating-utility-of-dapt-score-in-a-large-pooled-cohort-from-three-japanese-pci-studies
#7
Yusuke Yoshikawa, Hiroki Shiomi, Hirotoshi Watanabe, Masahiro Natsuaki, Hirokazu Kondo, Toshihiro Tamura, Yoshihisa Nakagawa, Takeshi Morimoto, Takeshi Kimura
Background -The DAPT score was developed to estimate ischemic and bleeding risks from the DAPT (Dual Antiplatelet Therapy) study. However, few studies validated its utility externally. We sought to validate the utility of the DAPT score in Japanese population. Methods -In a pooled cohort of three studies conducted in Japan (the CREDO Kyoto registry cohort-2, RESET and NEXT), we compared risks for ischemic and bleeding events from 13 to 36 months after percutaneous coronary intervention (PCI) between patients with DAPT score ≥2 (high-DS) and DAPT score <2 (low-DS)...
October 5, 2017: Circulation
https://www.readbyqxmd.com/read/28956889/risk-stratification-with-the-dapt-score-carefully-read-the-instructions-and-use-as-intended
#8
Davide Capodanno
No abstract text is available yet for this article.
October 5, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28870875/which-is-the-best-anti-aggregant-or-anti-coagulant-therapy-after-tavi-a-propensity-matched-analysis-from-the-iter-registry-the-management-of-dapt-after-tavi
#9
Fabrizio D'Ascenzo, Umberto Benedetto, Matteo Bianco, Federico Conrotto, Claudio Moretti, Augusto D'Onofrio, Marco Agrifoglio, Antonio Colombo, Flavio Ribichini, Giuseppe Tarantini, Maurizio D'Amico, Stefano Salizzoni, Fiorenzo Gaita
AIMS: Safety and efficacy of single vs. dual antiplatelet therapy (DAPT) in patients undergoing TAVI remain to be addressed. METHODS AND RESULTS: All consecutive patients enrolled in the ITER registry were included. Patients undergoing TAVI discharged with aspirin alone were compared to those assuming DAPT before and after selection with propensity score with matching. Subgroup analysis was performed for those on OAT. Prosthetic heart valve dysfunction at follow-up was the primary end point whereas all cause death, cardiovascular death, bleedings, vascular complications and cerebrovascular accidents were the secondary ones...
September 5, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28844033/state-of-the-art-duration-of-dual-antiplatelet-therapy-after-percutaneous-coronary-intervention-and-coronary-stent-implantation-past-present-and-future-perspectives
#10
Giuseppe Gargiulo, Marco Valgimigli, Davide Capodanno, John A Bittl
Evidence from studies published more than 10 years ago suggested that patients receiving first-generation drug-eluting stents (DES) needed dual antiplatelet therapy (DAPT) for at least 12 months. Current evidence from randomised controlled trials (RCT) reported within the past five years suggests that patients with stable ischaemic heart disease who receive newer-generation DES need DAPT for a minimum of three to six months. Patients who undergo stenting for an acute coronary syndrome benefit from DAPT for at least 12 months, but a Bayesian network meta-analysis confirms that extending DAPT beyond 12 months confers a trade-off between reduced ischaemic events and increased bleeding...
August 25, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28832589/a-counseling-program-on-nuisance-bleeding-improves-quality-of-life-in-patients-on-dual-antiplatelet-therapy-a-randomized-controlled-trial
#11
RANDOMIZED CONTROLLED TRIAL
Simone Biscaglia, Elisabetta Tonet, Rita Pavasini, Matteo Serenelli, Giulia Bugani, Paolo Cimaglia, Francesco Gallo, Giosafat Spitaleri, Annamaria Del Franco, Giorgio Aquila, Francesco Vieceli Dalla Sega, Matteo Tebaldi, Carlo Tumscitz, Roberto Ferrari, Gianluca Campo
BACKGROUND: Nuisance bleeding is a major determinant of quality of life and drug discontinuation in patients on dual antiplatelet therapy (DAPT). However, no randomized trial has been focused on the impact of nuisance bleeding on quality of life. METHODS: BATMAN is an investigator-driven, randomized, controlled, single-center, open trial (NCT02554006). Four hundred and forty-eight consecutive patients with indication to at least 6 months of DAPT were randomized to: i) multimodal counseling program focused on nuisance bleedings (interventional arm); ii) usual discharge process (control arm)...
2017: PloS One
https://www.readbyqxmd.com/read/28783201/validation-of-the-dapt-score-in-patients-randomized-to-6-or-12-months-clopidogrel-after-predominantly-second-generation-drug-eluting-stents
#12
Yukinori Harada, Jonathan Michel, Raphaela Lohaus, Katharina Mayer, Roberto Emmer, Anna Lena Lahmann, Roisin Colleran, Daniele Giacoppo, Annabelle Wolk, Jurrien M Ten Berg, Franz-Josef Neumann, Yaling Han, Tom Adriaenssens, Ralph Tölg, Melchior Seyfarth, Michael Maeng, Bernhard Zrenner, Claudius Jacobshagen, Jochen Wöhrle, Sebastian Kufner, Tanja Morath, Tareq Ibrahim, Isabell Bernlochner, Marcus Fischer, Heribert Schunkert, Karl-Ludwig Laugwitz, Julinda Mehilli, Robert A Byrne, Adnan Kastrati, Stefanie Schulz-Schüpke
The DAPT score is a recently-proposed decision tool for guiding optimal duration of dual antiplatelet therapy (DAPT). It showed modest accuracy in prior derivation and validation cohorts of patients with ≥12 months DAPT. This study was aimed to evaluate the validity of the DAPT score in a cohort of patients with 6 or 12 months DAPT after implantation of predominantly second-generation drug-eluting stents. We analyzed data of patients enrolled in the ISAR-SAFE trial. Patients were classified into low (<2) or high (≥2) DAPT score groups...
October 5, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28780077/individualized-antiplatelet-therapy-after-drug-eluting-stent-deployment-implication-of-clinical-trials-of-different-durations-of-dual-antiplatelet-therapy
#13
REVIEW
Masato Nakamura, Norihiro Kougame, Raisuke Iijima, Tsuyoshi Ono, Nobutaka Ikeda, Masahide Tokue, Fumiyuki Hayashi, Mami Watanabe, Hiroki Takenaka, Ryo Fukui, Hidehiko Hara
At present, there is consensus that prolonged dual antiplatelet therapy (DAPT) is effective to reduce cardiovascular events at the expense of bleeding complication events. A causal relationship of prolonged DAPT with an increase in mortality remains debatable, however, it appears to be obvious that bleeding complications are associated with an increase in cardiac events. Thus, individualized optimal DAPT duration balancing the risk and benefit of DAPT should be applied. In addition, strategy to minimize bleeding complications is highly recommended...
August 2, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28715833/in-patients-receiving-dapt-after-coronary-stents-the-precise-dapt-score-predicted-bleeding-moderately-well
#14
Ana Carolina Alba, Gordon Guyatt
No abstract text is available yet for this article.
July 18, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28605779/use-of-the-dual-antiplatelet-therapy-score-to-guide-treatment-duration-after-percutaneous-coronary-intervention
#15
RANDOMIZED CONTROLLED TRIAL
Raffaele Piccolo, Giuseppe Gargiulo, Anna Franzone, Andrea Santucci, Sara Ariotti, Andrea Baldo, Carlo Tumscitz, Aris Moschovitis, Stephan Windecker, Marco Valgimigli
Background: The dual-antiplatelet therapy (DAPT) score was developed to identify patients more likely to derive harm (score <2) or benefit (score ≥2) from prolonged DAPT after percutaneous coronary intervention (PCI). Objective: To evaluate the safety and efficacy of DAPT duration according to DAPT score. Design: Retrospective assessment of DAPT score-guided treatment duration in a randomized clinical trial. (ClinicalTrials.gov: NCT00611286)...
July 4, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28596132/crusade-score-is-superior-to-platelet-function-testing-for-prediction-of-bleeding-in-patients-following-coronary-interventions
#16
Junghee Bang, Sun Young Choi, Moo Hyun Kim, Victor Serebruany
Hypothetically, diminished platelet reactivity (PR) during dual antiplatelet therapy (DAPT) should cause extra major bleeding events (MBE), although definite evidence is lacking. Multiple scores have been proposed to stratify bleeding risk, but their predictive value during DAPT is unclear. We compared the performance of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) with PR testing to predict MBE in Korean patients with acute coronary syndrome...
July 2017: EBioMedicine
https://www.readbyqxmd.com/read/28587584/strategies-to-optimize-dual-antiplatelet-therapy-after-coronary-artery-stenting-in-acute-coronary-syndrome
#17
Bridget Paravattil, Hazem Elewa
The use of aspirin and a P2Y12 receptor antagonist as dual antiplatelet therapy (DAPT) has become the treatment of choice in patients with acute coronary syndrome (ACS) and percutaneous coronary intervention to prevent recurrent thrombotic events. Although DAPT is beneficial for most patients, few patients still experience recurrent thrombotic events and increased bleeding episodes. This article reviews current literature to identify various approaches that may enhance the DAPT benefit-risk ratio in patients with ACS...
July 2017: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28565887/safety-and-efficacy-of-catheter-based-left-atrial-appendage-closure-in-patients-with-contraindications-for-long-term-anticoagulation
#18
Adrian Seidel, Abdul S Parwani, Florian Krackhardt, Martin Huemer, Philipp Attanasio, Wilhelm Haverkamp, Burkert Pieske, Leif-Hendrik Boldt
BACKGROUND: Percutaneous left atrial appendage closure (LAAC) and the role of postinterventional anticoagulation often evokes controversy in daily practice. This study aimed to evaluate LAAC in patients with non-rheumatic atrial fibrillation, high thromboembolic risk and contraindications for long-term anticoagulation in a clinical scenario. METHODS: Between 2010-2015, LAAC was attempted in 118 patients (47 women). RESULTS: Devices were successfully implanted in 95% (Watchman™ device: N...
December 2017: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/28504270/antiplatelet-therapy-new-score-for-predicting-bleeding-risk-after-dapt
#19
Bastiaan Zwart, Jurriën M Ten Berg
No abstract text is available yet for this article.
May 15, 2017: Nature Reviews. Cardiology
https://www.readbyqxmd.com/read/28488370/patients-with-cirrhosis-who-have-coronary-artery-disease-treated-with-cardiac-stents-have-high-rates-of-gastrointestinal-bleeding-but-no-increased-mortality
#20
T Krill, G Brown, R A Weideman, D J Cipher, S J Spechler, E Brilakis, L A Feagins
BACKGROUND: Patients with coronary artery disease (CAD) treated with stents require dual antiplatelet therapy (DAPT). For cirrhotics, who often have varices and coagulopathy, it is not clear if the risk of gastrointestinal bleeding (GIB) should preclude use of DAPT. AIM: To compare GIB and mortality rates in cirrhotics with CAD treated medically or with stents. METHODS: Using institutional databases, we identified patients with cirrhosis and CAD treated with stents or medical therapy between January 2000-September 2015...
July 2017: Alimentary Pharmacology & Therapeutics
keyword
keyword
96854
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"